nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0509	CcSEcCtD
Crizotinib—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00973	0.0438	CcSEcCtD
Crizotinib—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00841	0.0379	CcSEcCtD
Crizotinib—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00817	0.0368	CcSEcCtD
Crizotinib—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00731	0.0329	CcSEcCtD
Crizotinib—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00703	0.0317	CcSEcCtD
Crizotinib—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00593	0.0267	CcSEcCtD
Crizotinib—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00589	0.0265	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00579	0.0261	CcSEcCtD
Crizotinib—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00579	0.0261	CcSEcCtD
Crizotinib—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00549	0.0247	CcSEcCtD
Crizotinib—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00543	0.0245	CcSEcCtD
Crizotinib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00502	0.0226	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00483	0.0217	CcSEcCtD
Crizotinib—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00481	0.0216	CcSEcCtD
Crizotinib—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.0042	0.0189	CcSEcCtD
Crizotinib—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00405	0.0183	CcSEcCtD
Crizotinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00382	0.0172	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00378	0.017	CcSEcCtD
Crizotinib—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.0037	0.0167	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0037	0.0167	CcSEcCtD
Crizotinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00339	0.0153	CcSEcCtD
Crizotinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00328	0.0148	CcSEcCtD
Crizotinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00326	0.0147	CcSEcCtD
Crizotinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00324	0.0146	CcSEcCtD
Crizotinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00324	0.0146	CcSEcCtD
Crizotinib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00317	0.0143	CcSEcCtD
Crizotinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00306	0.0138	CcSEcCtD
Crizotinib—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00296	0.0133	CcSEcCtD
Crizotinib—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00289	0.013	CcSEcCtD
Crizotinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00287	0.0129	CcSEcCtD
Crizotinib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00286	0.0129	CcSEcCtD
Crizotinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00285	0.0128	CcSEcCtD
Crizotinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0122	CcSEcCtD
Crizotinib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.0027	0.0121	CcSEcCtD
Crizotinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00262	0.0118	CcSEcCtD
Crizotinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.0026	0.0117	CcSEcCtD
Crizotinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00253	0.0114	CcSEcCtD
Crizotinib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00248	0.0112	CcSEcCtD
Crizotinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00234	0.0105	CcSEcCtD
Crizotinib—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00227	0.0102	CcSEcCtD
Crizotinib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00226	0.0102	CcSEcCtD
Crizotinib—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00222	0.01	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00963	CcSEcCtD
Crizotinib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0093	CcSEcCtD
Crizotinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00924	CcSEcCtD
Crizotinib—Shock—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00915	CcSEcCtD
Crizotinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00912	CcSEcCtD
Crizotinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00903	CcSEcCtD
Crizotinib—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00835	CcSEcCtD
Crizotinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00829	CcSEcCtD
Crizotinib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00818	CcSEcCtD
Crizotinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00808	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00803	CcSEcCtD
Crizotinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00802	CcSEcCtD
Crizotinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00795	CcSEcCtD
Crizotinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00735	CcSEcCtD
Crizotinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00667	CcSEcCtD
Crizotinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00636	CcSEcCtD
Crizotinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00615	CcSEcCtD
Crizotinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00591	CcSEcCtD
Crizotinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00586	CcSEcCtD
Crizotinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00586	CcSEcCtD
Crizotinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00552	CcSEcCtD
Crizotinib—EPHA6—nervous system—amyotrophic lateral sclerosis	0.00107	0.00314	CbGeAlD
Crizotinib—JAK3—nervous system—amyotrophic lateral sclerosis	0.00107	0.00314	CbGeAlD
Crizotinib—TESK1—spinal cord—amyotrophic lateral sclerosis	0.00106	0.00313	CbGeAlD
Crizotinib—DCLK1—nervous system—amyotrophic lateral sclerosis	0.00106	0.00312	CbGeAlD
Crizotinib—ACVR1B—cerebellum—amyotrophic lateral sclerosis	0.00105	0.0031	CbGeAlD
Crizotinib—STK4—nervous system—amyotrophic lateral sclerosis	0.00105	0.00309	CbGeAlD
Crizotinib—DSTYK—brain—amyotrophic lateral sclerosis	0.00104	0.00308	CbGeAlD
Crizotinib—JAK3—central nervous system—amyotrophic lateral sclerosis	0.00103	0.00303	CbGeAlD
Crizotinib—EPHA6—central nervous system—amyotrophic lateral sclerosis	0.00103	0.00303	CbGeAlD
Crizotinib—CSF1R—embryo—amyotrophic lateral sclerosis	0.00102	0.00301	CbGeAlD
Crizotinib—DCLK1—central nervous system—amyotrophic lateral sclerosis	0.00102	0.00301	CbGeAlD
Crizotinib—LTK—brain—amyotrophic lateral sclerosis	0.00102	0.00301	CbGeAlD
Crizotinib—CASK—brain—amyotrophic lateral sclerosis	0.00102	0.00301	CbGeAlD
Crizotinib—RIPK2—medulla oblongata—amyotrophic lateral sclerosis	0.00101	0.00298	CbGeAlD
Crizotinib—LIMK2—spinal cord—amyotrophic lateral sclerosis	0.00101	0.00298	CbGeAlD
Crizotinib—STK4—central nervous system—amyotrophic lateral sclerosis	0.00101	0.00297	CbGeAlD
Crizotinib—JAK3—cerebellum—amyotrophic lateral sclerosis	0.001	0.00296	CbGeAlD
Crizotinib—MAP3K12—spinal cord—amyotrophic lateral sclerosis	0.000999	0.00294	CbGeAlD
Crizotinib—ACVR1—spinal cord—amyotrophic lateral sclerosis	0.000999	0.00294	CbGeAlD
Crizotinib—DCLK1—cerebellum—amyotrophic lateral sclerosis	0.000998	0.00294	CbGeAlD
Crizotinib—TYRO3—nervous system—amyotrophic lateral sclerosis	0.00099	0.00292	CbGeAlD
Crizotinib—ALK—nervous system—amyotrophic lateral sclerosis	0.00099	0.00292	CbGeAlD
Crizotinib—FER—nervous system—amyotrophic lateral sclerosis	0.00099	0.00292	CbGeAlD
Crizotinib—EPHA5—nervous system—amyotrophic lateral sclerosis	0.00099	0.00292	CbGeAlD
Crizotinib—MAPK7—brain—amyotrophic lateral sclerosis	0.000989	0.00291	CbGeAlD
Crizotinib—STK4—cerebellum—amyotrophic lateral sclerosis	0.000986	0.0029	CbGeAlD
Crizotinib—LYN—nervous system—amyotrophic lateral sclerosis	0.000985	0.0029	CbGeAlD
Crizotinib—EPHA4—medulla oblongata—amyotrophic lateral sclerosis	0.000979	0.00288	CbGeAlD
Crizotinib—EPHA8—brain—amyotrophic lateral sclerosis	0.000979	0.00288	CbGeAlD
Crizotinib—FES—brain—amyotrophic lateral sclerosis	0.000979	0.00288	CbGeAlD
Crizotinib—BMPR1B—nervous system—amyotrophic lateral sclerosis	0.00097	0.00286	CbGeAlD
Crizotinib—MAP3K19—nervous system—amyotrophic lateral sclerosis	0.00097	0.00286	CbGeAlD
Crizotinib—EPHA5—central nervous system—amyotrophic lateral sclerosis	0.000953	0.00281	CbGeAlD
Crizotinib—ALK—central nervous system—amyotrophic lateral sclerosis	0.000953	0.00281	CbGeAlD
Crizotinib—FER—central nervous system—amyotrophic lateral sclerosis	0.000953	0.00281	CbGeAlD
Crizotinib—TYRO3—central nervous system—amyotrophic lateral sclerosis	0.000953	0.00281	CbGeAlD
Crizotinib—TNK2—nervous system—amyotrophic lateral sclerosis	0.000951	0.0028	CbGeAlD
Crizotinib—IGF1R—nervous system—amyotrophic lateral sclerosis	0.000951	0.0028	CbGeAlD
Crizotinib—LYN—central nervous system—amyotrophic lateral sclerosis	0.000949	0.00279	CbGeAlD
Crizotinib—BMP2K—spinal cord—amyotrophic lateral sclerosis	0.000942	0.00278	CbGeAlD
Crizotinib—TBK1—medulla oblongata—amyotrophic lateral sclerosis	0.00094	0.00277	CbGeAlD
Crizotinib—BMPR1B—central nervous system—amyotrophic lateral sclerosis	0.000934	0.00275	CbGeAlD
Crizotinib—MAP3K19—central nervous system—amyotrophic lateral sclerosis	0.000934	0.00275	CbGeAlD
Crizotinib—TYK2—medulla oblongata—amyotrophic lateral sclerosis	0.000934	0.00275	CbGeAlD
Crizotinib—EPHA5—cerebellum—amyotrophic lateral sclerosis	0.000932	0.00275	CbGeAlD
Crizotinib—TYRO3—cerebellum—amyotrophic lateral sclerosis	0.000932	0.00275	CbGeAlD
Crizotinib—FER—cerebellum—amyotrophic lateral sclerosis	0.000932	0.00275	CbGeAlD
Crizotinib—TIE1—nervous system—amyotrophic lateral sclerosis	0.000926	0.00273	CbGeAlD
Crizotinib—MET—brain—amyotrophic lateral sclerosis	0.000925	0.00273	CbGeAlD
Crizotinib—TNK1—cerebellum—amyotrophic lateral sclerosis	0.000922	0.00272	CbGeAlD
Crizotinib—TNK2—central nervous system—amyotrophic lateral sclerosis	0.000916	0.0027	CbGeAlD
Crizotinib—IGF1R—central nervous system—amyotrophic lateral sclerosis	0.000916	0.0027	CbGeAlD
Crizotinib—BMPR1B—cerebellum—amyotrophic lateral sclerosis	0.000913	0.00269	CbGeAlD
Crizotinib—RPS6KB1—medulla oblongata—amyotrophic lateral sclerosis	0.000904	0.00266	CbGeAlD
Crizotinib—RIPK2—spinal cord—amyotrophic lateral sclerosis	0.000903	0.00266	CbGeAlD
Crizotinib—AURKA—nervous system—amyotrophic lateral sclerosis	0.000902	0.00266	CbGeAlD
Crizotinib—TNK2—cerebellum—amyotrophic lateral sclerosis	0.000895	0.00264	CbGeAlD
Crizotinib—IGF1R—cerebellum—amyotrophic lateral sclerosis	0.000895	0.00264	CbGeAlD
Crizotinib—AXL—medulla oblongata—amyotrophic lateral sclerosis	0.000895	0.00264	CbGeAlD
Crizotinib—CDK7—brain—amyotrophic lateral sclerosis	0.000895	0.00264	CbGeAlD
Crizotinib—TESK1—nervous system—amyotrophic lateral sclerosis	0.000895	0.00264	CbGeAlD
Crizotinib—TIE1—central nervous system—amyotrophic lateral sclerosis	0.000891	0.00263	CbGeAlD
Crizotinib—TAOK2—brain—amyotrophic lateral sclerosis	0.000888	0.00262	CbGeAlD
Crizotinib—MAP4K2—cerebellum—amyotrophic lateral sclerosis	0.000883	0.0026	CbGeAlD
Crizotinib—STK3—cerebellum—amyotrophic lateral sclerosis	0.000871	0.00257	CbGeAlD
Crizotinib—TIE1—cerebellum—amyotrophic lateral sclerosis	0.000871	0.00257	CbGeAlD
Crizotinib—MERTK—nervous system—amyotrophic lateral sclerosis	0.00087	0.00256	CbGeAlD
Crizotinib—AURKA—central nervous system—amyotrophic lateral sclerosis	0.000868	0.00256	CbGeAlD
Crizotinib—SLK—medulla oblongata—amyotrophic lateral sclerosis	0.000862	0.00254	CbGeAlD
Crizotinib—TESK1—central nervous system—amyotrophic lateral sclerosis	0.000861	0.00254	CbGeAlD
Crizotinib—EPHB4—medulla oblongata—amyotrophic lateral sclerosis	0.000855	0.00252	CbGeAlD
Crizotinib—ACVR1B—brain—amyotrophic lateral sclerosis	0.000855	0.00252	CbGeAlD
Crizotinib—EPHA3—brain—amyotrophic lateral sclerosis	0.000855	0.00252	CbGeAlD
Crizotinib—LIMK2—nervous system—amyotrophic lateral sclerosis	0.000851	0.00251	CbGeAlD
Crizotinib—JAK2—medulla oblongata—amyotrophic lateral sclerosis	0.000849	0.0025	CbGeAlD
Crizotinib—ACVR1—nervous system—amyotrophic lateral sclerosis	0.000842	0.00248	CbGeAlD
Crizotinib—MAP3K12—nervous system—amyotrophic lateral sclerosis	0.000842	0.00248	CbGeAlD
Crizotinib—TESK1—cerebellum—amyotrophic lateral sclerosis	0.000842	0.00248	CbGeAlD
Crizotinib—PTK2—spinal cord—amyotrophic lateral sclerosis	0.000838	0.00247	CbGeAlD
Crizotinib—TBK1—spinal cord—amyotrophic lateral sclerosis	0.000838	0.00247	CbGeAlD
Crizotinib—MERTK—central nervous system—amyotrophic lateral sclerosis	0.000838	0.00247	CbGeAlD
Crizotinib—TYK2—spinal cord—amyotrophic lateral sclerosis	0.000832	0.00245	CbGeAlD
Crizotinib—STK35—nervous system—amyotrophic lateral sclerosis	0.000825	0.00243	CbGeAlD
Crizotinib—LIMK2—central nervous system—amyotrophic lateral sclerosis	0.000819	0.00241	CbGeAlD
Crizotinib—MERTK—cerebellum—amyotrophic lateral sclerosis	0.000819	0.00241	CbGeAlD
Crizotinib—MAP3K3—medulla oblongata—amyotrophic lateral sclerosis	0.000819	0.00241	CbGeAlD
Crizotinib—MAP4K5—medulla oblongata—amyotrophic lateral sclerosis	0.000819	0.00241	CbGeAlD
Crizotinib—TEK—medulla oblongata—amyotrophic lateral sclerosis	0.000819	0.00241	CbGeAlD
Crizotinib—JAK3—brain—amyotrophic lateral sclerosis	0.000816	0.0024	CbGeAlD
Crizotinib—EPHA6—brain—amyotrophic lateral sclerosis	0.000816	0.0024	CbGeAlD
Crizotinib—DCLK1—brain—amyotrophic lateral sclerosis	0.000811	0.00239	CbGeAlD
Crizotinib—ACVR1—central nervous system—amyotrophic lateral sclerosis	0.000811	0.00239	CbGeAlD
Crizotinib—MAP3K12—central nervous system—amyotrophic lateral sclerosis	0.000811	0.00239	CbGeAlD
Crizotinib—ABL1—embryo—amyotrophic lateral sclerosis	0.000808	0.00238	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—amyotrophic lateral sclerosis	0.000806	0.00238	CbGeAlD
Crizotinib—PLK4—brain—amyotrophic lateral sclerosis	0.000806	0.00237	CbGeAlD
Crizotinib—STK4—brain—amyotrophic lateral sclerosis	0.000801	0.00236	CbGeAlD
Crizotinib—LIMK2—cerebellum—amyotrophic lateral sclerosis	0.000801	0.00236	CbGeAlD
Crizotinib—AXL—spinal cord—amyotrophic lateral sclerosis	0.000798	0.00235	CbGeAlD
Crizotinib—NUAK2—cerebellum—amyotrophic lateral sclerosis	0.000798	0.00235	CbGeAlD
Crizotinib—STK35—central nervous system—amyotrophic lateral sclerosis	0.000794	0.00234	CbGeAlD
Crizotinib—BMP2K—nervous system—amyotrophic lateral sclerosis	0.000794	0.00234	CbGeAlD
Crizotinib—FLT3—cerebellum—amyotrophic lateral sclerosis	0.000792	0.00233	CbGeAlD
Crizotinib—ACVR1—cerebellum—amyotrophic lateral sclerosis	0.000792	0.00233	CbGeAlD
Crizotinib—MAP3K12—cerebellum—amyotrophic lateral sclerosis	0.000792	0.00233	CbGeAlD
Crizotinib—EPHB6—medulla oblongata—amyotrophic lateral sclerosis	0.000782	0.0023	CbGeAlD
Crizotinib—STK35—cerebellum—amyotrophic lateral sclerosis	0.000776	0.00229	CbGeAlD
Crizotinib—SLK—spinal cord—amyotrophic lateral sclerosis	0.000768	0.00226	CbGeAlD
Crizotinib—PTK2B—nervous system—amyotrophic lateral sclerosis	0.000767	0.00226	CbGeAlD
Crizotinib—BMP2K—central nervous system—amyotrophic lateral sclerosis	0.000765	0.00225	CbGeAlD
Crizotinib—EPHB4—spinal cord—amyotrophic lateral sclerosis	0.000763	0.00225	CbGeAlD
Crizotinib—JAK2—spinal cord—amyotrophic lateral sclerosis	0.000757	0.00223	CbGeAlD
Crizotinib—TYRO3—brain—amyotrophic lateral sclerosis	0.000757	0.00223	CbGeAlD
Crizotinib—FER—brain—amyotrophic lateral sclerosis	0.000757	0.00223	CbGeAlD
Crizotinib—ALK—brain—amyotrophic lateral sclerosis	0.000757	0.00223	CbGeAlD
Crizotinib—EPHA5—brain—amyotrophic lateral sclerosis	0.000757	0.00223	CbGeAlD
Crizotinib—ABL2—cerebellum—amyotrophic lateral sclerosis	0.000757	0.00223	CbGeAlD
Crizotinib—YES1—medulla oblongata—amyotrophic lateral sclerosis	0.000756	0.00223	CbGeAlD
Crizotinib—LYN—brain—amyotrophic lateral sclerosis	0.000753	0.00222	CbGeAlD
Crizotinib—TNK1—brain—amyotrophic lateral sclerosis	0.000749	0.00221	CbGeAlD
Crizotinib—BMP2K—cerebellum—amyotrophic lateral sclerosis	0.000747	0.0022	CbGeAlD
Crizotinib—TAOK3—medulla oblongata—amyotrophic lateral sclerosis	0.000746	0.0022	CbGeAlD
Crizotinib—BMPR1B—brain—amyotrophic lateral sclerosis	0.000742	0.00218	CbGeAlD
Crizotinib—MAP4K1—brain—amyotrophic lateral sclerosis	0.000742	0.00218	CbGeAlD
Crizotinib—MAP3K19—brain—amyotrophic lateral sclerosis	0.000742	0.00218	CbGeAlD
Crizotinib—ABL1—brainstem—amyotrophic lateral sclerosis	0.00074	0.00218	CbGeAlD
Crizotinib—PTK2B—central nervous system—amyotrophic lateral sclerosis	0.000738	0.00218	CbGeAlD
Crizotinib—EPHA4—nervous system—amyotrophic lateral sclerosis	0.000735	0.00217	CbGeAlD
Crizotinib—MAP3K3—spinal cord—amyotrophic lateral sclerosis	0.00073	0.00215	CbGeAlD
Crizotinib—TEK—spinal cord—amyotrophic lateral sclerosis	0.00073	0.00215	CbGeAlD
Crizotinib—MAP4K5—spinal cord—amyotrophic lateral sclerosis	0.00073	0.00215	CbGeAlD
Crizotinib—IGF1R—brain—amyotrophic lateral sclerosis	0.000727	0.00214	CbGeAlD
Crizotinib—TNK2—brain—amyotrophic lateral sclerosis	0.000727	0.00214	CbGeAlD
Crizotinib—PTK2B—cerebellum—amyotrophic lateral sclerosis	0.000722	0.00213	CbGeAlD
Crizotinib—MAP3K2—nervous system—amyotrophic lateral sclerosis	0.000721	0.00212	CbGeAlD
Crizotinib—MAP4K2—brain—amyotrophic lateral sclerosis	0.000717	0.00211	CbGeAlD
Crizotinib—RIPK2—cerebellum—amyotrophic lateral sclerosis	0.000716	0.00211	CbGeAlD
Crizotinib—EPHA4—central nervous system—amyotrophic lateral sclerosis	0.000708	0.00209	CbGeAlD
Crizotinib—STK3—brain—amyotrophic lateral sclerosis	0.000707	0.00208	CbGeAlD
Crizotinib—TIE1—brain—amyotrophic lateral sclerosis	0.000707	0.00208	CbGeAlD
Crizotinib—TBK1—nervous system—amyotrophic lateral sclerosis	0.000706	0.00208	CbGeAlD
Crizotinib—PTK2—nervous system—amyotrophic lateral sclerosis	0.000706	0.00208	CbGeAlD
Crizotinib—TYK2—nervous system—amyotrophic lateral sclerosis	0.000701	0.00207	CbGeAlD
Crizotinib—EPHB6—spinal cord—amyotrophic lateral sclerosis	0.000698	0.00206	CbGeAlD
Crizotinib—MAP3K2—central nervous system—amyotrophic lateral sclerosis	0.000694	0.00205	CbGeAlD
Crizotinib—EPHA4—cerebellum—amyotrophic lateral sclerosis	0.000692	0.00204	CbGeAlD
Crizotinib—AURKA—brain—amyotrophic lateral sclerosis	0.000689	0.00203	CbGeAlD
Crizotinib—TESK1—brain—amyotrophic lateral sclerosis	0.000684	0.00201	CbGeAlD
Crizotinib—TBK1—central nervous system—amyotrophic lateral sclerosis	0.00068	0.002	CbGeAlD
Crizotinib—PTK2—central nervous system—amyotrophic lateral sclerosis	0.00068	0.002	CbGeAlD
Crizotinib—RPS6KB1—nervous system—amyotrophic lateral sclerosis	0.000679	0.002	CbGeAlD
Crizotinib—MAP3K2—cerebellum—amyotrophic lateral sclerosis	0.000679	0.002	CbGeAlD
Crizotinib—TYK2—central nervous system—amyotrophic lateral sclerosis	0.000675	0.00199	CbGeAlD
Crizotinib—FGR—nervous system—amyotrophic lateral sclerosis	0.000675	0.00199	CbGeAlD
Crizotinib—YES1—spinal cord—amyotrophic lateral sclerosis	0.000674	0.00199	CbGeAlD
Crizotinib—AXL—nervous system—amyotrophic lateral sclerosis	0.000673	0.00198	CbGeAlD
Crizotinib—TAOK3—spinal cord—amyotrophic lateral sclerosis	0.000666	0.00196	CbGeAlD
Crizotinib—MERTK—brain—amyotrophic lateral sclerosis	0.000665	0.00196	CbGeAlD
Crizotinib—PTK2—cerebellum—amyotrophic lateral sclerosis	0.000665	0.00196	CbGeAlD
Crizotinib—TBK1—cerebellum—amyotrophic lateral sclerosis	0.000665	0.00196	CbGeAlD
Crizotinib—TYK2—cerebellum—amyotrophic lateral sclerosis	0.00066	0.00194	CbGeAlD
Crizotinib—RPS6KB1—central nervous system—amyotrophic lateral sclerosis	0.000654	0.00193	CbGeAlD
Crizotinib—CSF1R—medulla oblongata—amyotrophic lateral sclerosis	0.000653	0.00192	CbGeAlD
Crizotinib—IRAK1—cerebellum—amyotrophic lateral sclerosis	0.000651	0.00192	CbGeAlD
Crizotinib—LIMK2—brain—amyotrophic lateral sclerosis	0.000651	0.00192	CbGeAlD
Crizotinib—FGR—central nervous system—amyotrophic lateral sclerosis	0.00065	0.00191	CbGeAlD
Crizotinib—SRC—spinal cord—amyotrophic lateral sclerosis	0.000649	0.00191	CbGeAlD
Crizotinib—NUAK2—brain—amyotrophic lateral sclerosis	0.000648	0.00191	CbGeAlD
Crizotinib—AXL—central nervous system—amyotrophic lateral sclerosis	0.000647	0.00191	CbGeAlD
Crizotinib—MAP3K12—brain—amyotrophic lateral sclerosis	0.000644	0.0019	CbGeAlD
Crizotinib—ACVR1—brain—amyotrophic lateral sclerosis	0.000644	0.0019	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—amyotrophic lateral sclerosis	0.000639	0.00188	CbGeAlD
Crizotinib—JAK2—nervous system—amyotrophic lateral sclerosis	0.000638	0.00188	CbGeAlD
Crizotinib—AXL—cerebellum—amyotrophic lateral sclerosis	0.000633	0.00186	CbGeAlD
Crizotinib—STK35—brain—amyotrophic lateral sclerosis	0.000631	0.00186	CbGeAlD
Crizotinib—EPHA2—nervous system—amyotrophic lateral sclerosis	0.00063	0.00186	CbGeAlD
Crizotinib—MAP3K3—nervous system—amyotrophic lateral sclerosis	0.000615	0.00181	CbGeAlD
Crizotinib—MAP4K5—nervous system—amyotrophic lateral sclerosis	0.000615	0.00181	CbGeAlD
Crizotinib—TEK—nervous system—amyotrophic lateral sclerosis	0.000615	0.00181	CbGeAlD
Crizotinib—ABL2—brain—amyotrophic lateral sclerosis	0.000615	0.00181	CbGeAlD
Crizotinib—JAK2—central nervous system—amyotrophic lateral sclerosis	0.000614	0.00181	CbGeAlD
Crizotinib—SLK—cerebellum—amyotrophic lateral sclerosis	0.000609	0.00179	CbGeAlD
Crizotinib—EPHA2—central nervous system—amyotrophic lateral sclerosis	0.000607	0.00179	CbGeAlD
Crizotinib—BMP2K—brain—amyotrophic lateral sclerosis	0.000607	0.00179	CbGeAlD
Crizotinib—EPHB4—cerebellum—amyotrophic lateral sclerosis	0.000605	0.00178	CbGeAlD
Crizotinib—JAK2—cerebellum—amyotrophic lateral sclerosis	0.000601	0.00177	CbGeAlD
Crizotinib—MAP3K3—central nervous system—amyotrophic lateral sclerosis	0.000592	0.00174	CbGeAlD
Crizotinib—MAP4K5—central nervous system—amyotrophic lateral sclerosis	0.000592	0.00174	CbGeAlD
Crizotinib—TEK—central nervous system—amyotrophic lateral sclerosis	0.000592	0.00174	CbGeAlD
Crizotinib—EPHB6—nervous system—amyotrophic lateral sclerosis	0.000588	0.00173	CbGeAlD
Crizotinib—PTK2B—brain—amyotrophic lateral sclerosis	0.000586	0.00173	CbGeAlD
Crizotinib—CSF1R—spinal cord—amyotrophic lateral sclerosis	0.000582	0.00172	CbGeAlD
Crizotinib—RIPK2—brain—amyotrophic lateral sclerosis	0.000581	0.00171	CbGeAlD
Crizotinib—MAP4K5—cerebellum—amyotrophic lateral sclerosis	0.000579	0.00171	CbGeAlD
Crizotinib—TEK—cerebellum—amyotrophic lateral sclerosis	0.000579	0.00171	CbGeAlD
Crizotinib—MAP3K3—cerebellum—amyotrophic lateral sclerosis	0.000579	0.00171	CbGeAlD
Crizotinib—YES1—nervous system—amyotrophic lateral sclerosis	0.000568	0.00167	CbGeAlD
Crizotinib—EPHB6—central nervous system—amyotrophic lateral sclerosis	0.000566	0.00167	CbGeAlD
Crizotinib—STK10—nervous system—amyotrophic lateral sclerosis	0.000563	0.00166	CbGeAlD
Crizotinib—EPHA4—brain—amyotrophic lateral sclerosis	0.000562	0.00166	CbGeAlD
Crizotinib—TAOK3—nervous system—amyotrophic lateral sclerosis	0.000561	0.00165	CbGeAlD
Crizotinib—EPHB6—cerebellum—amyotrophic lateral sclerosis	0.000553	0.00163	CbGeAlD
Crizotinib—MAP3K2—brain—amyotrophic lateral sclerosis	0.000551	0.00162	CbGeAlD
Crizotinib—YES1—central nervous system—amyotrophic lateral sclerosis	0.000547	0.00161	CbGeAlD
Crizotinib—SRC—nervous system—amyotrophic lateral sclerosis	0.000546	0.00161	CbGeAlD
Crizotinib—STK10—central nervous system—amyotrophic lateral sclerosis	0.000542	0.0016	CbGeAlD
Crizotinib—TAOK3—central nervous system—amyotrophic lateral sclerosis	0.00054	0.00159	CbGeAlD
Crizotinib—PTK2—brain—amyotrophic lateral sclerosis	0.00054	0.00159	CbGeAlD
Crizotinib—TBK1—brain—amyotrophic lateral sclerosis	0.00054	0.00159	CbGeAlD
Crizotinib—TYK2—brain—amyotrophic lateral sclerosis	0.000536	0.00158	CbGeAlD
Crizotinib—YES1—cerebellum—amyotrophic lateral sclerosis	0.000535	0.00157	CbGeAlD
Crizotinib—STK10—cerebellum—amyotrophic lateral sclerosis	0.00053	0.00156	CbGeAlD
Crizotinib—IRAK1—brain—amyotrophic lateral sclerosis	0.000529	0.00156	CbGeAlD
Crizotinib—TAOK3—cerebellum—amyotrophic lateral sclerosis	0.000528	0.00155	CbGeAlD
Crizotinib—SRC—central nervous system—amyotrophic lateral sclerosis	0.000526	0.00155	CbGeAlD
Crizotinib—RPS6KB1—brain—amyotrophic lateral sclerosis	0.000519	0.00153	CbGeAlD
Crizotinib—ABL1—medulla oblongata—amyotrophic lateral sclerosis	0.000516	0.00152	CbGeAlD
Crizotinib—FGR—brain—amyotrophic lateral sclerosis	0.000516	0.00152	CbGeAlD
Crizotinib—SRC—cerebellum—amyotrophic lateral sclerosis	0.000514	0.00151	CbGeAlD
Crizotinib—AXL—brain—amyotrophic lateral sclerosis	0.000514	0.00151	CbGeAlD
Crizotinib—SLK—brain—amyotrophic lateral sclerosis	0.000495	0.00146	CbGeAlD
Crizotinib—EPHB4—brain—amyotrophic lateral sclerosis	0.000491	0.00145	CbGeAlD
Crizotinib—CSF1R—nervous system—amyotrophic lateral sclerosis	0.000491	0.00145	CbGeAlD
Crizotinib—JAK2—brain—amyotrophic lateral sclerosis	0.000488	0.00144	CbGeAlD
Crizotinib—EPHA2—brain—amyotrophic lateral sclerosis	0.000482	0.00142	CbGeAlD
Crizotinib—CSF1R—central nervous system—amyotrophic lateral sclerosis	0.000472	0.00139	CbGeAlD
Crizotinib—TEK—brain—amyotrophic lateral sclerosis	0.00047	0.00138	CbGeAlD
Crizotinib—MAP3K3—brain—amyotrophic lateral sclerosis	0.00047	0.00138	CbGeAlD
Crizotinib—MAP4K5—brain—amyotrophic lateral sclerosis	0.00047	0.00138	CbGeAlD
Crizotinib—CSF1R—cerebellum—amyotrophic lateral sclerosis	0.000462	0.00136	CbGeAlD
Crizotinib—ABL1—spinal cord—amyotrophic lateral sclerosis	0.00046	0.00136	CbGeAlD
Crizotinib—EPHB6—brain—amyotrophic lateral sclerosis	0.000449	0.00132	CbGeAlD
Crizotinib—YES1—brain—amyotrophic lateral sclerosis	0.000434	0.00128	CbGeAlD
Crizotinib—STK10—brain—amyotrophic lateral sclerosis	0.00043	0.00127	CbGeAlD
Crizotinib—TAOK3—brain—amyotrophic lateral sclerosis	0.000429	0.00126	CbGeAlD
Crizotinib—SRC—brain—amyotrophic lateral sclerosis	0.000418	0.00123	CbGeAlD
Crizotinib—ABL1—nervous system—amyotrophic lateral sclerosis	0.000388	0.00114	CbGeAlD
Crizotinib—CSF1R—brain—amyotrophic lateral sclerosis	0.000375	0.0011	CbGeAlD
Crizotinib—ABL1—central nervous system—amyotrophic lateral sclerosis	0.000373	0.0011	CbGeAlD
Crizotinib—ABL1—cerebellum—amyotrophic lateral sclerosis	0.000365	0.00108	CbGeAlD
Crizotinib—ABL1—brain—amyotrophic lateral sclerosis	0.000296	0.000873	CbGeAlD
Crizotinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000251	0.00074	CbGeAlD
Crizotinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00017	0.000502	CbGeAlD
Crizotinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000164	0.000483	CbGeAlD
Crizotinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.00016	0.000473	CbGeAlD
Crizotinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000143	0.000422	CbGeAlD
Crizotinib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000121	0.000355	CbGeAlD
Crizotinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000116	0.000342	CbGeAlD
Crizotinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000113	0.000334	CbGeAlD
Crizotinib—ABCB1—brain—amyotrophic lateral sclerosis	9.22e-05	0.000272	CbGeAlD
Crizotinib—CDK7—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.87e-05	4.26e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.86e-05	4.24e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—C3—amyotrophic lateral sclerosis	1.86e-05	4.24e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.86e-05	4.23e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.85e-05	4.22e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.85e-05	4.21e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	1.85e-05	4.21e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.84e-05	4.2e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.83e-05	4.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CASP9—amyotrophic lateral sclerosis	1.83e-05	4.17e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.83e-05	4.17e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.83e-05	4.17e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ATF1—amyotrophic lateral sclerosis	1.82e-05	4.15e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.82e-05	4.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.81e-05	4.14e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—ERBB4—amyotrophic lateral sclerosis	1.81e-05	4.13e-05	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—TP53—amyotrophic lateral sclerosis	1.81e-05	4.13e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.81e-05	4.13e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—ERBB4—amyotrophic lateral sclerosis	1.8e-05	4.11e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—C3—amyotrophic lateral sclerosis	1.8e-05	4.1e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.8e-05	4.1e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.77e-05	4.04e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.76e-05	4.02e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.74e-05	3.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.74e-05	3.98e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.74e-05	3.97e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CASP9—amyotrophic lateral sclerosis	1.73e-05	3.95e-05	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.73e-05	3.94e-05	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.72e-05	3.93e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—SQSTM1—amyotrophic lateral sclerosis	1.72e-05	3.92e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.71e-05	3.91e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.71e-05	3.91e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD40LG—amyotrophic lateral sclerosis	1.7e-05	3.88e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.7e-05	3.87e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.7e-05	3.87e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.7e-05	3.87e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ERBB4—amyotrophic lateral sclerosis	1.69e-05	3.86e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD40LG—amyotrophic lateral sclerosis	1.69e-05	3.86e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.69e-05	3.85e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.69e-05	3.84e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—MMP9—amyotrophic lateral sclerosis	1.66e-05	3.8e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.66e-05	3.79e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.66e-05	3.79e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.64e-05	3.73e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.64e-05	3.73e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.63e-05	3.72e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.62e-05	3.69e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.62e-05	3.69e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ATF1—amyotrophic lateral sclerosis	1.61e-05	3.68e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—PTGS2—amyotrophic lateral sclerosis	1.61e-05	3.67e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.6e-05	3.65e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CASP9—amyotrophic lateral sclerosis	1.6e-05	3.65e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—APOE—amyotrophic lateral sclerosis	1.6e-05	3.64e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD40LG—amyotrophic lateral sclerosis	1.59e-05	3.63e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.59e-05	3.63e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.59e-05	3.63e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.59e-05	3.63e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.57e-05	3.58e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.57e-05	3.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—ERBB4—amyotrophic lateral sclerosis	1.56e-05	3.57e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.55e-05	3.54e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.55e-05	3.53e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.55e-05	3.53e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.54e-05	3.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.54e-05	3.51e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CASP9—amyotrophic lateral sclerosis	1.53e-05	3.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.53e-05	3.49e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.53e-05	3.49e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.52e-05	3.46e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.52e-05	3.46e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.51e-05	3.44e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—C3—amyotrophic lateral sclerosis	1.5e-05	3.43e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—C3—amyotrophic lateral sclerosis	1.5e-05	3.42e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.5e-05	3.41e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—VEGFA—amyotrophic lateral sclerosis	1.49e-05	3.41e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.49e-05	3.4e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ERBB4—amyotrophic lateral sclerosis	1.48e-05	3.38e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TP53—amyotrophic lateral sclerosis	1.48e-05	3.38e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.48e-05	3.38e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.48e-05	3.37e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.47e-05	3.35e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.46e-05	3.34e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.46e-05	3.34e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TP53—amyotrophic lateral sclerosis	1.46e-05	3.33e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.45e-05	3.32e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.45e-05	3.31e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.45e-05	3.3e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.45e-05	3.3e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.45e-05	3.3e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.44e-05	3.29e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.44e-05	3.29e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.44e-05	3.27e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.44e-05	3.27e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.43e-05	3.27e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.43e-05	3.27e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.43e-05	3.27e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CASP9—amyotrophic lateral sclerosis	1.42e-05	3.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—C3—amyotrophic lateral sclerosis	1.41e-05	3.21e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.4e-05	3.19e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD40LG—amyotrophic lateral sclerosis	1.4e-05	3.18e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.39e-05	3.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.38e-05	3.14e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.37e-05	3.13e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB4—amyotrophic lateral sclerosis	1.37e-05	3.12e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.37e-05	3.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.36e-05	3.1e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.36e-05	3.09e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.35e-05	3.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.35e-05	3.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.34e-05	3.06e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.32e-05	3.02e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.31e-05	3e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB4—amyotrophic lateral sclerosis	1.31e-05	3e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.3e-05	2.97e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.3e-05	2.96e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.29e-05	2.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.28e-05	2.92e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.28e-05	2.91e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.26e-05	2.87e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.26e-05	2.86e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.24e-05	2.82e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD40LG—amyotrophic lateral sclerosis	1.24e-05	2.82e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—C3—amyotrophic lateral sclerosis	1.23e-05	2.81e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.23e-05	2.81e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.23e-05	2.8e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.22e-05	2.79e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.21e-05	2.77e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB4—amyotrophic lateral sclerosis	1.21e-05	2.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—APOE—amyotrophic lateral sclerosis	1.21e-05	2.76e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.2e-05	2.74e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.19e-05	2.71e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.19e-05	2.7e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.18e-05	2.69e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.18e-05	2.68e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.17e-05	2.67e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.15e-05	2.63e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.14e-05	2.61e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.12e-05	2.56e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.12e-05	2.55e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.12e-05	2.55e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.11e-05	2.53e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.1e-05	2.51e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.1e-05	2.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.1e-05	2.5e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PTGS2—amyotrophic lateral sclerosis	1.09e-05	2.5e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—C3—amyotrophic lateral sclerosis	1.09e-05	2.49e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—amyotrophic lateral sclerosis	1.09e-05	2.48e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—amyotrophic lateral sclerosis	1.08e-05	2.47e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.07e-05	2.43e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—APOE—amyotrophic lateral sclerosis	1.06e-05	2.42e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.06e-05	2.41e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.05e-05	2.39e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.04e-05	2.38e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.03e-05	2.35e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.02e-05	2.33e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—amyotrophic lateral sclerosis	1.02e-05	2.32e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.02e-05	2.32e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1e-05	2.29e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.98e-06	2.28e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.93e-06	2.27e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.92e-06	2.26e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.84e-06	2.24e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.73e-06	2.22e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.72e-06	2.22e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	9.6e-06	2.19e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.52e-06	2.17e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.5e-06	2.17e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.43e-06	2.15e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.41e-06	2.15e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—APOE—amyotrophic lateral sclerosis	9.38e-06	2.14e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	9.3e-06	2.12e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.3e-06	2.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.24e-06	2.11e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.13e-06	2.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.1e-06	2.08e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.06e-06	2.07e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.02e-06	2.06e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—amyotrophic lateral sclerosis	8.93e-06	2.04e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.9e-06	2.03e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.63e-06	1.97e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	8.58e-06	1.96e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.49e-06	1.94e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.47e-06	1.93e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.47e-06	1.93e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.35e-06	1.9e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—amyotrophic lateral sclerosis	8.29e-06	1.89e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.15e-06	1.86e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.99e-06	1.82e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.99e-06	1.82e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.97e-06	1.82e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—amyotrophic lateral sclerosis	7.9e-06	1.8e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.83e-06	1.79e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.75e-06	1.77e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.72e-06	1.76e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.49e-06	1.71e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.48e-06	1.71e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.42e-06	1.69e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.4e-06	1.69e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.33e-06	1.67e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.3e-06	1.66e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—amyotrophic lateral sclerosis	7.26e-06	1.66e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.18e-06	1.64e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.11e-06	1.62e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.06e-06	1.61e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	7.05e-06	1.61e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7e-06	1.6e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.92e-06	1.58e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.72e-06	1.53e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.65e-06	1.52e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.57e-06	1.5e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.55e-06	1.49e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—amyotrophic lateral sclerosis	6.43e-06	1.47e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.4e-06	1.46e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.31e-06	1.44e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.22e-06	1.42e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	6.16e-06	1.41e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.15e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.13e-06	1.4e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.04e-06	1.38e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.04e-06	1.38e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.85e-06	1.33e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.76e-06	1.31e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.65e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.44e-06	1.24e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.43e-06	1.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.39e-06	1.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.09e-06	1.16e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.02e-06	1.15e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.95e-06	1.13e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.89e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.72e-06	1.08e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.7e-06	1.07e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	4.65e-06	1.06e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.57e-06	1.04e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.56e-06	1.04e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.46e-06	1.02e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.22e-06	9.63e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.18e-06	9.53e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.01e-06	9.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.95e-06	9.01e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.79e-06	8.64e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.69e-06	8.42e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.55e-06	8.09e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.48e-06	7.94e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.46e-06	7.88e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.19e-06	7.27e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.03e-06	6.9e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2.86e-06	6.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.68e-06	6.11e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.96e-06	4.48e-06	CbGpPWpGaD
